Human TRAIL R1/TNFRSF10A Affinity Purified Polyclonal Ab (100 UG)【科瑞奥博】

产品中心

当前位置：首页>产品中心

Human TRAIL R1/TNFRSF10A Affinity Purified Polyclonal Ab (100 UG)

货号： AF347 基本售价： 4996.9 元规格： -

产品信息

概述
货号	AF347
别名	APO2; CD261 antigen; CD261; cytotoxic TRAIL receptor; Death receptor 4; DR4 TRAIL receptor 1; DR4; TNF-related apoptosis inducing ligand receptor 1; TNF-related apoptosis-inducing ligand receptor 1; TNFRSF10A; TRAIL-R1; TRAILR-1; TRAILR1MGC9365; tumor necrosis factor receptor superfamily member 10A; tumor necrosis factor receptor superfamily, member 10a
全称	TRAIL Receptor 1
反应种属	Human
应用	Western Blot(1 µg/mL) Immunohistochemistry(5-15 µg/mL)
目标/特异性	Detects human TRAIL R1/TNFRSF10A in direct ELISAs and Western blots. In Western blots, approximately 10% cross-reactivity with recombinant human (rh) TRAIL R2 is observed and less than 1% cross-reactivity with rhTRAIL R3 and rhTRAIL R4 is observed.
使用方法	Western Blot: 1 µg/mL Immunohistochemistry: 5-15 µg/mL Neutralization: Measured by its ability to neutralize TRAIL R1/TNFRSF10A-mediated inhibition of cytotoxicity in the L‑929 mouse fibroblast cell line. The Neutralization Dose (ND₅₀) is typically 0.02-0.055 µg/mL in the presence of 10 ng/mL Recombinant Human TRAIL R1/TNFRSF10A Fc Chimera, 12 ng/mL Recombinant Human TRAIL/TNFSF10, a cross-linking antibody, Mouse polyHistidine Monoclonal Antibody, and 1 µg/mL actinomycin D.
来源	Polyclonal Goat IgG
产品组分

性能
供应商	R&D Systems
Entrez Gene IDs	8797 (Human)
应用文献
R&D Systems personnel manually curate a database that contains references using R&D Systems products. The data collected includes not only links to publications in PubMed, but also provides information about sample types, species, and experimental conditions. Doxorubicin overcomes resistance to drozitumab by antagonizing Inhibitor of Apoptosis Proteins (IAPs). Authors: Zinonos I, Labrinidis A, Liapis V, Hay S, Panagopoulos V, Denichilo M, Ponomarev V, Ingman W, Atkins G, Findlay D, Zannettino A, Evdokiou A Anticancer Res, 2014;34(12):7007-20. Species: Human Sample Type: whole cells Application: Flow Epigenetic silencing of death receptor 4 mediates tumor necrosis factor-related apoptosis-inducing ligand resistance in gliomas. Authors: Elias A, Siegelin MD, Steinmuller A, von Deimling A, Lass U, Korn B, Mueller W Clin. Cancer Res., 2009;15(17):5457-65. Species: Human Sample Type: Whole Cells Application: Neut Trichostatin A sensitizes human ovarian cancer cells to TRAIL-induced apoptosis by down-regulation of c-FLIPL via inhibition of EGFR pathway. Authors: Park SJ, Kim MJ, Kim HB, Sohn HY, Bae JH, Kang CD, Kim SH Biochem. Pharmacol., 2009;77(8):1328-36. Species: Human Sample Type: Cell Lysates Application: WB Down-regulation of FoxO-dependent c-FLIP expression mediates TRAIL-induced apoptosis in activated hepatic stellate cells. Authors: Park SJ, Sohn HY, Yoon J, Park SI Cell. Signal., 2009;21(10):1495-503. Species: Human Sample Type: Whole Cells Application: Flow Myricetin sensitizes malignant glioma cells to TRAIL-mediated apoptosis by down-regulation of the short isoform of FLIP and bcl-2. Authors: Siegelin MD, Gaiser T, Habel A, Siegelin Y Cancer Lett., 2009;283(2):230-8. Species: Human Sample Type: Whole Cells Application: WB TRAIL recombinant adenovirus triggers robust apoptosis in multidrug-resistant HL-60/Vinc cells preferentially through death receptor DR5. Authors: Wu CH, Kao CH, Safa AR Hum. Gene Ther., 2008;19(7):731-43. Species: Human Sample Type: Whole Cells Application: Neut Downmodulation of dimethyl transferase activity enhances tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis in prostate cancer cells. Authors: Festuccia C, Gravina GL, DAlessandro AM, Millimaggi D, Di Rocco C, Dolo V, Ricevuto E, Vicentini C, Bologna M Int. J. Oncol., 2008;33(2):381-8. Species: Human Sample Type: Cell Lysates Application: WB Arsenic trioxide sensitizes human glioma cells, but not normal astrocytes, to TRAIL-induced apoptosis via CCAAT/enhancer-binding protein homologous protein-dependent DR5 up-regulation. Authors: Kim EH, Yoon MJ, Kim SU, Kwon TK, Sohn S, Choi KS Cancer Res., 2008;68(1):266-75. Species: Human Sample Type: Whole Cells Application: Flow Differential response of p53 and p21 on HDAC inhibitor-mediated apoptosis in HCT116 colon cancer cells in vitro and in vivo. Authors: Zopf S, Neureiter D, Bouralexis S, Abt T, Glaser KB, Okamoto K, Ganslmayer M, Hahn EG, Herold C, Ocker M Int. J. Oncol., 2007;31(6):1391-402. Species: Human Sample Type: Cell Lysates Application: WB Acquired resistance to TRAIL-induced apoptosis in human ovarian cancer cells is conferred by increased turnover of mature caspase-3. Authors: Lane D, Cote M, Grondin R, Couture MC, Piche A Mol. Cancer Ther., 2006;5(3):509-21. Species: Human Sample Type: Whole Cells Application: WB EphB4 provides survival advantage to squamous cell carcinoma of the head and neck. Authors: Masood R, Kumar SR, Sinha UK, Crowe DL, Krasnoperov V, Reddy RK, Zozulya S, Singh J, Xia G, Broek D, Schonthal AH, Gill PS Int. J. Cancer, 2006;119(6):1236-48. Species: Human Sample Type: Cell Lysates Application: WB P-glycoprotein enhances TRAIL-triggered apoptosis in multidrug resistant cancer cells by interacting with the death receptor DR5. Authors: Park SJ, Wu CH, Choi MR, Najafi F, Emami A, Safa AR Biochem. Pharmacol., 2006;72(3):293-307. Species: Human Sample Type: Whole Cells Application: Flow Death receptors, Fas and TRAIL receptors, are involved in human osteoclast apoptosis. Authors: Roux S, Lambert-Comeau P, Saint-Pierre C, Lepine M, Sawan B, Parent JL Biochem. Biophys. Res. Commun., 2005;333(1):42-50. Species: Human Sample Type: Whole Tissue Application: IHC Paraffin-embedded Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) induces rheumatoid arthritis synovial fibroblast proliferation through mitogen-activated protein kinases and phosphatidylinositol 3-kinase/Akt. Authors: Morel J, Audo R, Hahne M, Combe B J. Biol. Chem., 2005;280(16):15709-18. Species: Human Sample Type: Whole Cells Application: Flow Absence of caspase 8 and high expression of PED protect primitive neural cells from cell death. Authors: Ricci-Vitiani L, Pedini F, Mollinari C, Condorelli G, Bonci D, Bez A, Colombo A, Parati E, Peschle C, De Maria R J. Exp. Med., 2004;200(10):1257-66. Species: Human Sample Type: Whole Cells Application: Flow Synergistic induction of apoptosis in breast cancer cells by cotreatment with butyrate and TNF-alpha, TRAIL, or anti-Fas agonist antibody involves enhancement of death receptors' signaling and requires P21(waf1). Authors: Chopin V, Slomianny C, Hondermarck H, Le Bourhis X Exp. Cell Res., 2004;298(2):560-73. Species: Human Sample Type: Cell Lysates Application: WB TNF-related apoptosis-inducing ligand mediates human neuronal apoptosis: links to HIV-1-associated dementia. Authors: Ryan LA, Peng H, Erichsen DA, Huang Y, Persidsky Y, Zhou Y, Gendelman HE, Zheng J J. Neuroimmunol., 2004;148(1):127-39. Species: Human Sample Type: Whole Tissue Application: IHC Frozen Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) decoy receptor TRAIL-R3 is up-regulated by p53 in breast tumor cells through a mechanism involving an intronic p53-binding site. Authors: Ruiz de Almodovar C, Ruiz-Ruiz C, Rodriguez A, Ortiz-Ferron G, Redondo JM, Lopez-Rivas A J. Biol. Chem., 2004;279(6):4093-101. Species: Human Sample Type: Cell Lysates Application: WB Tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) and TNF-alpha promote the NF-kappaB-dependent maturation of normal and leukemic myeloid cells. Authors: Secchiero P, Milani D, Gonelli A, Melloni E, Campioni D, Gibellini D, Capitani S, Zauli G J. Leukoc. Biol., 2003;74(2):223-32. Species: Human Sample Type: Whole Cells Application: Neut Enhanced expression of the apoptosis inducing ligand TRAIL in mononuclear cells after myocardial infarction. Authors: Nakajima H, Yanase N, Oshima K, Sasame A, Fukazawa S, Takata R, Mukai K, Yamashina A, Mizuguchi J Jpn Heart J, 2003;44(6):833-44. Species: Human Sample Type: Whole Tissue Application: IHC Paraffin-embedded Interferon-alpha sensitizes human hepatoma cells to TRAIL-induced apoptosis through DR5 upregulation and NF-kappa B inactivation. Authors: Shigeno M, Nakao K, Ichikawa T, Suzuki K, Kawakami A, Abiru S, Miyazoe S, Nakagawa Y, Ishikawa H, Hamasaki K, Nakata K, Ishii N, Eguchi K Oncogene, 2003;22(11):1653-62. Species: Human Sample Type: Whole Cells Application: Flow Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) sequentially upregulates nitric oxide and prostanoid production in primary human endothelial cells. Authors: Zauli G, Pandolfi A, Gonelli A, Di Pietro R, Guarnieri S, Ciabattoni G, Rana R, Vitale M, Secchiero P Circ. Res., 2003;92(7):732-40. Species: Human Sample Type: Whole Cells Application: Flow Regulation of tumour necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced apoptosis in Burkitt's lymphoma cell lines. Authors: Mouzakiti A, Packham G Br. J. Haematol., 2003;122(1):61-9. Species: Human Sample Type: Cell Lysates Application: WB An antibody against DR4 (TRAIL-R1) in combination with doxorubicin selectively kills malignant but not normal prostate cells. Authors: Voelkel-Johnson C Cancer Biol. Ther., 2003;2(3):283-90. Species: Human Sample Type: Whole Cells Application: Neut Apoptosis-mediating receptor-ligand systems in human retinal pigment epithelial cells. Authors: Hueber A, Aduckathil S, Kociok N, Welsandt G, Dinslage S, Kirchhof B, Esser PJ Chin. Med. J., 2002;240(7):551-6. Species: Human Sample Type: Whole Tissue Application: IHC Fresh/Frozen Inflammatory cytokine regulation of TRAIL-mediated apoptosis in thyroid epithelial cells. Authors: Bretz JD, Mezosi E, Giordano TJ, Gauger PG, Thompson NW, Baker JR Cell Death Differ., 2002;9(3):274-86. Species: Human Sample Type: Whole Cells Application: Flow Activation of NF-kappaB and upregulation of intracellular anti-apoptotic proteins via the IGF-1/Akt signaling in human multiple myeloma cells: therapeutic implications. Authors: Mitsiades CS, Mitsiades N, Poulaki V, Schlossman R, Akiyama M, Chauhan D, Hideshima T, Treon SP, Munshi NC, Richardson PG, Anderson KC Oncogene, 2002;21(37):5673-83. Species: Human Sample Type: Whole Cells Application: Flow
纯化方式	Antigen Affinity-purified
免疫原	S. frugiperda insect ovarian cell line Sf 21-derived recombinant human TRAIL R1/TNFRSF10A Ala24-Asn239 Accession # AAC51226
内毒素水平	<0.10 EU per 1 μg of the antibody by the LAL method.
生物活性	Human
标记	Unconjugated
溶解方法	Reconstitute at 0.2 mg/mL in sterile PBS.
背景	Human TRAIL R1, also called DR4, is a type 1, TNF R family, membrane protein which is a receptor for TRAIL (APO2 ligand). In the TNF superfamily nomenclature, TRAIL RI is referred to as TNFRSF10A. TRAIL R1 cDNA encodes a 468 amino acid residue precursor protein containing extracellular cysteine-rich domains, a transmembrane domain and a cytoplasmic death domain. Among the TNF receptor family proteins, TRAIL R1 is most closely related to TRAIL R2/DR5, sharing 55% amino acid sequence identity. Binding of trimeric TRAIL to TRAIL R1 induces apoptosis. The induction of apoptosis likely requires oligomerization of the receptor. The human TRAIL R1/Fc chimera neutralizes the ability of TRAIL to induce apoptosis. Besides TRAIL R1, an additional TRAIL R2/DR5, which tranduces apoptosis signal, and two TRAIL decoy receptors, which antagonize TRAIL-induced apoptosis, have been reported.
运输条件	Blue Ice
存放说明	-20℃
参考文献	Pan, G. et al. (1997) Science 276:111. Golstein, P. (1997) Curr. Biol. 7:R750.

参考图片

TRAIL R1/TNFRSF10A Inhibition of TRAIL/TNFSF10-induced Cytotoxicity and Neutralization by Human TRAIL R1/TNFRSF10A Antibody. In the presence of a cross-linking antibody, Mouse polyHistidine Monoclonal Antibody (Catalog # MAB050) and the metabolic inhibitor actinomycin D (1 µg/mL), Recombinant Human TRAIL R1/TNFRSF10A Fc Chimera (Catalog # 347‑DR) inhibits Recombinant Human TRAIL/TNFSF10 (Catalog # 375‑TL) induced cytotoxicity in the L‑929 mouse fibroblast cell line in a dose-dependent manner (orange line), as measured by crystal violet staining. Under these conditions, inhibition of Recombinant Human TRAIL/TNFSF10 (12 ng/mL) activity elicited by Recombinant Human TRAIL R1/TNFRSF10A Fc Chimera (10 ng/mL) is neutralized (green line) by increasing concentrations of Goat Anti-Human TRAIL R1/
TNFRSF10A Antigen Affinity-purified Polyclonal Antibody (Catalog # AF347). The ND₅₀ is typically 0.02‑0.055 µg/mL.

Detection of Human TRAIL R1/TNFRSF10A by Western Blot. Western blot shows lysates of TF‑1 human erythroleukemic cell line. PVDF membrane was probed with 1 µg/mL of Goat Anti-Human TRAIL R1/TNFRSF10A Antigen Affinity-purified Polyclonal Antibody (Catalog # AF347) followed by HRP-conjugated Anti-Goat IgG Secondary Antibody (Catalog # HAF019). A specific band was detected for TRAIL R1/TNFRSF10A at approximately 50 kDa (as indicated). This experiment was conducted under reducing conditions.

TRAIL R1/TNFRSF10A in Human Brain. TRAIL R1/TNFRSF10A was detected in immersion fixed paraffin-embedded sections of human brain using Goat Anti-Human TRAIL R1/TNFRSF10A Antigen Affinity-purified Polyclonal Antibody (Catalog # AF347) at 10 µg/mL overnight at 4 °C. Tissue was stained using the Anti-Goat HRP-DAB Cell & Tissue Staining Kit (brown; Catalog # CTS008) and counterstained with hematoxylin (blue). Specific staining was localized to cytoplasm in neurons. View our protocol for Chromogenic IHC Staining of Paraffin-embedded Tissue Sections.